Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

NCT03919292 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT03919292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03919292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1/2
Overall status
Suspended
Start date
May 1, 2019
Completion date
January 31, 2031
Enrollment
83 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult